# Concentra Group Holdings Parent Inc. (CON) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $34.47, market value $4.4 billion.

## Valuation
- **P/E (trailing): 22.2×** (5-yr avg 14.2×, 3-yr avg 14.2×). Concentra Group Holdings Parent Inc. trades at 22.2× trailing earnings, well above its own five-year average of 14.2×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 9.2×**. The shares trade at 9.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 13.0×**. Enterprise value is 13.0× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 6.1%** (5-yr avg 8.7%). Free cash flow equals 6.1% of the market value, below its five-year average of 8.7%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 4.5%**. The inverse of the P/E: 4.5% of the price is earned each year.

## Profitability
- **Operating margin: 16.4%**. 16.4% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 7.7%**. 7.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 42.3%**. 42.3% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 15.7%**. Return on all capital, debt included, is 15.7%: comfortably above what that capital costs.
- **Return on assets: 7.0%**. Each dollar of assets produces 7.0% of profit.

## Growth
- **Revenue growth (1 yr): 13.9%** (3-yr 7.9%/yr). Revenue grew 13.9% over the last year.
- **EPS growth (1 yr): -11.0%** (3-yr -6.7%/yr). Earnings per share fell 11.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -4.8%/yr**. Free cash flow has compounded at -4.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 4.00**. Debt is 4.00 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.3×**. It would take 3.3 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 1.14** (quick 1.14). Current assets cover the next year's liabilities 1.14 times.
- **Altman Z-score: 2.44**. A Z-score of 2.44 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.73%** ($0.25 per share, trailing). Concentra Group Holdings Parent Inc. yields 0.73%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 19%** (12% of free cash flow). 19% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 2**. 2 straight years of increases.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Concentra Group Holdings Parent Inc.; the consensus is strong_buy, with an average price target of $39.88 (+16% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 47.7%** (YTD 76.1%, 3-mo 36.1%). The shares are up 47.7% over twelve months including dividends.
- **From 52-week high: -4.0%** (85.9% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 0.50** (volatility 28%). Beta of 0.50 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CON · Page: https://foliofundamentals.com/stocks/con

Not investment advice.